c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) screening component and a therapeutic component. c-TRAK TN aims to assess whether ctDNA screening can be used to detect residual disease following patients standard primary treatment for triple negative breast cancer, and will assess the safety and activity of the investigational medicinal product pembrolizumab.